Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate vs Deferred Docetaxel + Leuprolide in High-Risk Prostate Cancer
NCT00283062Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2005
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial of docetaxel in prostate cancer (PCa) (4 arms), sponsored by Sanofi. Primary endpoint: Progression-free Survival at 3 years. Started Dec 2005; status: completed.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00283062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00283062.